acceptability
Clinical Impression of Severity Index (CISI–PD), 19
scale attribute, 18–19, 24
Addenbrooke’s Cognitive Examination (ACE and revised
ACE–R), cognitive screening, 198–199, 209
administrative burden, 25–26
AIMS (Abnormal Involuntary Movement Scale), dyskinesia, 84,
86–87, 96
Alzheimer’s disease, 165
Alzheimer’s Disease Assessment Scale–Cognition
(ACAD–Cog), cognitive screening, 198, 199–200, 209
American Quality of Well–Being Scale (QWB), cost utility, 158,
160, 163
analysis of variance (ANOVA), 31
anchor-based approaches, minimal clinically relevant change
(MCRC), 43–44
anhedonia
Chapman Scales for Physical and Social Anhedonia, 181–182
Parkinson’s disease, 173–174
scales, 182–183
Snith-Hamilton Pleasure Scale (SHAPS), 181
anxiety disorders
assessment, 186–187
rating scales, 186, 187–188
anxiety scales, 186, 187–188
Anxiety Status Inventory (ASI), 190
assessment, 191–192
Beck Anxiety Inventory (BAI), 188–189
Hamilton Anxiety Rating Scale (HARS), 190–191
Hospital Anxiety and Depression Scale–Anxiety Subscale
(HADS–A), 189
Neuropsychiatric Inventory–Anxiety Subscale (NPI–A), 191
Self-Rating Anxiety Scale (SAS), 189–190
State Trait Anxiety Inventory (STAI), 190
Anxiety Status Inventory (SAI), 188, 190, 192
Apathy Evaluation Scale (AES), 175–176
Apathy Inventory (AI), 175, 176, 177–178
Apathy Scale (AS), 175, 176–177
apathy scales, 182
Apathy Evaluation Scale (AES), 175–176
Apathy Inventory (AI), 177–178
Apathy Scale (AS), 176–177
classification of scales, 176
Parkinson’s disease, 173–174
Assessment of Parkinson’s Disease Scale (APDS), motor
fluctuations, 101–103
assessment of quality of life (AQOL)
cost utility, 156, 158, 159, 161
PD patients, 154
assessment of scales
Classical Test Theory (CTT), 18–26
Rasch analysis, 26–34
Autonomic Dysfunction in Parkinson’s Disease, dysautonomia,
218, 224–225, 228
Baylor Hallucinations Questionnaire, psychosis, 263, 264,
266–267
Beck Anxiety Inventory (BAI), 188–189, 192
Beck Depression Inventory (BDI), 286, 288, 290–291
Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE–AD), psychosis, 263, 264, 269–270
Belastungsfragebogen Parkinson Kurzversion (BELA-P-k), quality of life, 125, 130, 135
“between-patients” score change, minimal clinically relevant change (MCRC), 44
binary scaling, 8
Bonferroni correction, 31
Brief Psychiatric Rating Scale (BPRS), 174, 263, 264, 270–271
Cambridge Cognitive Assessment (CAMCOG and CAMCOG–R), cognitive screening, 198, 200–201, 209
celling effects, 9, 19
Center for Epidemiologic Studies Depression Scale (CES–D), 286, 288, 295–296
Chalder Fatigue Questionnaire (CFQ), 235, 236, 249–250
der change over time, measuring, 13–14
Chapman Scales for Physical and Social Anhedonia, 175, 176, 181–182
Classical Test Theory (CTT) assessment, 18–26
cceptual and measurement model, 18
feasibility and acceptability, 18–19
nterpretability, 23, 25
item scaling, 18
psychometric attributes and criteria, 24
reliability, 19–20
nter and administrative burdens, 25–26
responsiveness, 22–23
validation, 17–18
validity, 20–22
clinical anchors, 44
Clinical Dyskinesia Rating Scale (CDRS), 84, 86, 91–92, 96
Clinical Global Impression–Improvement scale, 67
Clinical Global Impression Scale (CGIS) fatigue, 235, 236, 251–252
psychos, 263, 264, 275–276
Clincial Global Impression–Severity (CGI-s), 78
Clinical Impression of Severity Index (CISI–PD), 19
Clinician Interview-based Impression of Change scale, 67
clinimetrics
Beck Depression Inventory (BDI), 290
Center for Epidemiologic Studies Depression Scale (CES–D), 296
Chalder Fatigue Questionnaire, 250
Clinical Global Impression Scale (CGIS), 252
Cornell Scale for Depression in Dementia (CSDD), 294
developments in, 54–55
Fatigue Assessment Inventory (FAI), 241–242
Fatigue Severity Inventory (FSI), 247–248
Fatigue Severity Scale (FSS), 239
 Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT–F), 243
Geriatric Depression Scale (GDS), 293
Hamilton Depression Rating Scale (Ham–D), 287–288
Hoehn and Yahr (HY) scale, 118–119
Hospital Anxiety and Depression Scale (HADS), 291
Montgomery–Asberg Depression Rating Scale (MADRS), 289
Multidimensional Fatigue Inventory (MFI), 244–245
Parkinson Fatigue Scale (PFS), 246–247
Parkinson’s Disease Sleep Scale (PDSS), 309
Pittsburgh Sleep Quality Index (PSQI), 310–311
SCOPA–Sleep, 312–313
Treatment Response Scale (TRS), 106–107
Unified Parkinson’s Disease Rating Scale (UPDRS), 65–69
UPDRS, 295
Visual Analogue Scales (VAS), 251
Zung Self-Rating Depression Scale (SDS), 292
cognitive impairment
Parkinson’s disease, 195–197
screening instruments, 197, 198
cognitive impairment screening
Addenbrooke’s Cognitive Examination (ACE and revised ACE–R), 198–199
Cambridge Cognitive Assessment (CAMCOG and CAMCOG–R), 200–201
neurodegeneration scale, 201–202
future perspective, 210
onvenience, 198, 209, 210
amin-Mental Parkinson (MMP), 202–203
amin-Mental State Examination (MMSE), 203
Montreal Cognitive Assessment (MOCA), 204–205
Parkinson Neuropsychometric Dementia Assessment (PANDA), 206–207
Parkinson’s Disease Cognitive Rating Scale (PD–CRS), 205–206
Parkinson’s Disease Dementia–Short Screen (PDD–SS), 206
neurodegeneration scale, 208, 210
cognitive pretesting, 11
Ohen’s Kappa correlations, 12
olumbia University Rating Scale (CURS), 52, 100
ommon factor model, 12
omorbidities
Chalder Fatigue Questionnaire, 249
Fatigue Assessment Inventory (FAI), 241
Fatigue Impact Scale for Daily Use (D–FIS), 248
Fatigue Severity Inventory (FSI), 247
Fatigue Severity Scale (FSS), 239
Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT–F), 242
Hoehn and Yahr (HY) scale, 116–117
MDS–UPDRS, 76
multidimensional Fatigue Inventory (MFI), 244
Parkinson Fatigue Scale (PFS), 246
Parkinson’s Disease Sleep Scale (PDSS), 308
Pittsburgh Sleep Quality Index (PSQI), 310
SCOPA–Sleep scale, 312
Unified Parkinson’s Disease Rating Scale (UPDRS), 63–64
COMPASS (Composite Autonomic Symptom Scale), dysautonomia, 218, 220, 228
Confi rmative Fit Index (CFI), 13
onfirmatory factor analysis, 13
Consensus-based Standard for selection of health status
Measurement Instruments (COSMIN) panel, 21, 135
construct validity, 21
content evidence, 11
content validity, 20, 24
content validity ratio (CVR), 6
convergent validity, 21–22
Core Assessment Programs for Intracerebral Transplantation and Surgical Interventional Therapies for PD (CAPIT/ CAPSIT), 65
Core Assessment Programs for Surgical Interventional Therapies in PD (CAPSIT–PD) diary, 99, 101, 107, 110–111
Cornell Scale for Depression in Dementia (CSDD), 286, 288, 293–294
Cost-effectiveness (CE), 146, 149
cost of illness (COI), 145, 164
assessment in patients with Parkinson's disease, 146, 149
resource components, 150–151
studies in PD, 147–148
cost utility (CU), 146
15D, 157, 158, 160, 163
assessment of quality of life (AQOL), 156, 158, 159, 161
direct and indirect measurements of preference-based outcomes, 149, 152
direct utility assessment, 152
EQ–SD, 157, 159, 161
evaluating PD patient preferences, 153–154
Health Utility Index (HUI), 157, 158, 159, 161–162
Index of Health Related Quality of Life (IHQI), 162
indirect utility assessment, 152
preference-based outcomes, 164–165
Quality of Well-Being Scale (QWB), 158, 160, 163
Rosser disability/distress scale, 158, 160, 162
depression scales, 152–164
SF–60, 157, 162–163
standard gamble (SG), 152
time trade-off (TTO), 156
utility measurements in PD patients, 155
visual analogue scale (VAS), 156
criterion validity, 20–21, 24
Cronbach's alpha, 12, 20, 29
cross-cultural validity, 22
Delphi approach, 5, 6
dementia, psychosis scales, 268–270
dementia rating scales, 198, 201–202, 209
depression rating scales, 286, 288
Beck Depression Inventory (BDI), 290–291
Center for Epidemiologic Studies Depression Scale (CES–D), 295–296
clinical practice and research, 285–287
Cornell Scale for Depression in Dementia (CSDD), 293–294
depression in Parkinson's disease (dPD), 284
Geriatric Depression Scale (GDS), 292–293
Hamilton Depression Rating Scale (Ham–D), 287–289
Hospital Anxiety and Depression Scale (HADS), 291–292
literature search strategy, 284
methods, 284
Montgomery–Asberg Depression Rating Scale (MADRS), 289
problems when using for dPD, 284–285
recommendations, 296–299
Unified Parkinson's Disease Rating Scale (UPDRS) Part I, 295
Zung Self-Rating Depression Scale (SDS), 292
differential item functioning (DIF), 14, 31, 33
disabilities, 52
disablement process, 52, 53
disease models, developments in, 52–54
distribution approaches, minimal clinically relevant change (MCRC), 44–45
divergent validity, 21–22
domain and scaling, relationship, 7
domain of interest, 5
dysautonomia rating scales
Autonomic Dysfunction in Parkinson's Disease, 224–225
Autonomic Scale for Outcomes in Parkinson's disease (SCOPA–AUT), 217, 219
clinical perspectives, 228–229
COMPASS (Composite Autonomic Symptom Scale), 220
Freiburg Questionnaire, 224
Hobson Scale, 226
L-threo DOPS Evaluation Scale, 226
methods, 216
Non-Motor Symptoms Questionnaire for Parkinson's disease (NMS Quest), 220–221
Non-Motor Symptoms Scale (NMSS), 221–223
Orthostatic Grading Scale (OGS), 225–226
orthostatic hypotension, 215–216
scale characteristics, 227
cost utility (CU), 264
scale characteristics, 227
cost utility (CU), 264
scale and questionnaires, 216–217, 218, 228, 229
Senard et al. 1997, 226
UPDRS and MDS–UPDRS, 223–224
dyskinesia, drug-induced, in PD, 84–85
dyskinesia scales
AIMS (Abnormal Involuntary Movement Scale), 86–87
Clinical Dyskinesia Rating Scale (CDRS), 91–92
Lang–Fahn Activities of Daily Living Dyskinesia Scale, 92–93
MDS–UPDRS, 88–89
Obeso Dyskinesia Rating Scale (CAPIT), 89–90
Parkinson Disease Dyskinesia Scale (PDYS–26), 93–94
recommendations, 95–96
Rush dyskinesia scale, 90–91
Unified Dyskinesia Rating Scale (UDysRS), 94–95
UPDRS, 87–88
effect size, 45
Epworth Sleepiness Scale, 26
equivalent forms reliability, 20
Essay on the Shaking Palsy, Parkinson, 55
EUROQOL 5-Dimensions (EQ–5D)
cost utility, 145, 164
assessment in patients with Parkinson's disease, 146, 149
resource components, 150–151
studies in PD, 147–148
cost utility (CU), 146
15D, 157, 158, 160, 163
assessment of quality of life (AQOL), 156, 158, 159, 161
direct and indirect measurements of preference-based outcomes, 149, 152
direct utility assessment, 152
EQ–SD, 157, 159, 161
evaluating PD patient preferences, 153–154
Health Utility Index (HUI), 157, 158, 159, 161–162
Index of Health Related Quality of Life (IHQI), 162
indirect utility assessment, 152
preference-based outcomes, 164–165
Quality of Well-Being Scale (QWB), 158, 160, 163
Rosser disability/distress scale, 158, 160, 162
depression scales, 152–164
SF–60, 157, 162–163
standard gamble (SG), 152
time trade-off (TTO), 156
utility measurements in PD patients, 155
visual analogue scale (VAS), 156
criterion validity, 20–21, 24
Cronbach's alpha, 12, 20, 29
cross-cultural validity, 22
Delphi approach, 5, 6
dementia, psychosis scales, 268–270
dementia Rating Scale, cognitive screening, 198, 201–202, 209
depression rating scales, 286, 288
Beck Depression Inventory (BDI), 290–291
Center for Epidemiologic Studies Depression Scale (CES–D), 295–296
clinical practice and research, 285–287
Cornell Scale for Depression in Dementia (CSDD), 293–294
depression in Parkinson's disease (dPD), 284
Geriatric Depression Scale (GDS), 292–293
Hamilton Depression Rating Scale (Ham–D), 287–289
Hospital Anxiety and Depression Scale (HADS), 291–292
literature search strategy, 284
methods, 284
Montgomery–Asberg Depression Rating Scale (MADRS), 289
problems when using for dPD, 284–285
recommendations, 296–299
Unified Parkinson's Disease Rating Scale (UPDRS) Part I, 295
Zung Self-Rating Depression Scale (SDS), 292
differential item functioning (DIF), 14, 31, 33
disabilities, 52
disablement process, 52, 53
disease models, developments in, 52–54
distribution approaches, minimal clinically relevant change (MCRC), 44–45
divergent validity, 21–22
domain and scaling, relationship, 7
domain of interest, 5
dysautonomia rating scales
Autonomic Dysfunction in Parkinson's Disease, 224–225
Autonomic Scale for Outcomes in Parkinson's disease (SCOPA–AUT), 217, 219
clinical perspectives, 228–229
COMPASS (Composite Autonomic Symptom Scale), 220
Freiburg Questionnaire, 224
Hobson Scale, 226
L-threo DOPS Evaluation Scale, 226
methods, 216
Non-Motor Symptoms Questionnaire for Parkinson's disease (NMS Quest), 220–221
Non-Motor Symptoms Scale (NMSS), 221–223
Orthostatic Grading Scale (OGS), 225–226
orthostatic hypotension, 215–216
scale characteristics, 227
cost utility (CU), 264
scale characteristics, 227
cost utility (CU), 264
scale and questionnaires, 216–217, 218, 228, 229
Senard et al. 1997, 226
UPDRS and MDS–UPDRS, 223–224
dyskinesia, drug-induced, in PD, 84–85
dyskinesia scales
AIMS (Abnormal Involuntary Movement Scale), 86–87
Clinical Dyskinesia Rating Scale (CDRS), 91–92
Lang–Fahn Activities of Daily Living Dyskinesia Scale, 92–93
MDS–UPDRS, 88–89
Obeso Dyskinesia Rating Scale (CAPIT), 89–90
Parkinson Disease Dyskinesia Scale (PDYS–26), 93–94
recommendations, 95–96
Rush dyskinesia scale, 90–91
Unified Dyskinesia Rating Scale (UDysRS), 94–95
UPDRS, 87–88
effect size, 45
Epworth Sleepiness Scale, 26
equivalent forms reliability, 20
Essay on the Shaking Palsy, Parkinson, 55
EUROQOL 5-Dimensions (EQ–5D)
cost utility, 145, 164
assessment in patients with Parkinson's disease, 146, 149
resource components, 150–151
studies in PD, 147–148

focus group, 5, 6
Food and Drug Administration (FDA), 10
Fragebogen Parkinson Lebensqualität (PLQ), 125, 133, 135
Freiburg Questionnaire, dysautonomia, 218, 224, 228
Frontal Systems Behavior Scale (FSBS), 174
F-statistic, 23
Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT–F), 26, 235, 236, 242–244
Geriatric Depression Scale (GDS), 286, 288, 292–293
Hamilton Anxiety Rating Scale (HARS), 188, 190–191, 192
Hamilton Depression Rating Scale (Ham–D), 286, 287–289
handicaps, 52
Hauser Parkinson’s Disease Diary, motor fluctuations, 99, 101, 107, 110–111
health, concept, 164
health economic studies. See also cost utility (CU)
comparative studies, 145–146
noncomparative studies, 145
health-related quality of life (HRQOL) scales, 44
Belastungsfragebogen Parkinson Kurzversion (BELA–P–k), 130
EUROQOL 5-Dimensions (EQ–5D), 126–127
Fragebogen Parkinson Lebensqualität (PLQ), 133
key evaluation points, 135
literature search strategy, 124–125
Medical Outcomes Study 36-Item Short–Form Health Survey (SF–36), 127–128
methods, 124–125
Nottingham Health Profile (NHP), 126
Parkinson’s Disease Quality of Life Questionnaire (PDQ–39), 132
Parkinson’s Disease Quality of Life Scale (PDQUALIF), 132–133
Parkinson’s Disease Questionnaire (PDQ–8), 130–131
Parkinson’s Disease Questionnaire Short Form (PDQ–8), 131
Parkinson’s Impact Scale (PIMS), 131–132
Parkinson’s Problem Schedule (PPS), 133–134
Quality of Life Questionnaire 15D (15D), 128–129
Questions on Life Satisfaction–Movement Disorders (QLS–MD) module, 129–130
recommendations, 134–137
Scales for Outcomes in Parkinson’s Disease–Psychosocial (SCOPA–PS), 134
Schedule for the Evaluation of Individual Quality of Life–Direct Weighting (SEIQOL–DW), 128
Sickness Impact Profile (SIP), 125–126
WHO Quality of Life Assessment Short Version (WHOQOL–BREF), 129
health status (HS), 124
Health Utility Index (HUI)
cost utility, 157, 158, 159, 161–162
patients with PD, 154
Hobson scale, dysautonomia, 218, 226, 228
Hoehn and Yahr scale, 52, 115, 116
clinimetric issues, 118
comparing original and modified, 116
future, 120
handling comorbidities, 116–117
key evaluation issues, 117–119
MCRD, 119
MCRID, 119
reliability, 118
responsiveness, 119
scale description, 116–117
strengths and weaknesses, 119–120
structure, 116
use by multiple authors, 118
use in PD and across disease spectrum, 117–118
validity, 118–119
Hospital Anxiety and Depression Scale (HADS), 26, 286, 288, 291–292
Hospital Anxiety and Depression Scale–Anxiety Subscale (HADS–A), 188, 189, 192
hypothesis testing validity, 24
IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials), 56
Impact on Participation and Autonomy questionnaire, 26
impairments, 52
Index of Health Related Quality of Life (IHQL), cost utility, 162
insomnia, sleep disturbances, 307–308
Intermediate Scale for Assessment of PD (ISAPD), motor fluctuations, 100, 102, 103
internal consistency, 9, 12, 19–20, 24
internal validity, 22, 23
International Classification of Functioning, Disability and Health (ICF), 52, 53
International Classification of Impairments, Disabilities and Handicaps (ICIDH), 52–53
interpretability, classical test theory (CTT), 23, 25
inter-rater reliability, 11–12
intra-class correlations, 12
Item Response Theory (IRT), 14, 17–18
item scaling, SCOPA–sleep scale, 19
Kappa correlations, 12
Known-groups validity, 22
Kruskal–Wallis test, 22, 23
Kuder–Richardson formula 20 (KR 20), 20
Lang–Fahn Activities of Daily Living Dyskinesia Scale, dyskinesia, 84, 86, 92–93, 96
Latent Trait Theories, 17–18
Likert rating, 8–9
Likert scales, 7, 8, 190
Lille Apathy Rating Scale (LARS), 174, 175, 176, 178–179
Lin’s concordance coefficient (LCC), 12
literature search
clinimetric issues, 118
comparing original and modified, 116
future, 120
handling comorbidities, 116–117
key evaluation issues, 117–119
MCRD, 119
MCRID, 119
reliability, 118
responsiveness, 119
minimal clinically important change (MCIC), UPDRS, 66–67
minimal clinically important difference (MCID), 25, 43
minimal clinically relevant change (MCRC), 42
anchor-based approaches, 43–44
distribution-based approaches, 44–45
effect size and standard deviation, 45
methods to calculate, 43–45
standard error of measurement (SEM), 45
uses of, 45–46
Minimal clinically relevant difference (MCDR), 42
Hoehn and Yahr (HY) scale, 119
MDS–UPDRS, 78–79
UPDRS, 66–68
Minimal clinically relevant incremental difference (MCRID)
Hoehn and Yahr (HY) scale, 119
MDS–UPDRS, 78–79
UPDRS, 66–68
Minimal important change (MIC), 25
Mini-Mental Parkinson (MMP), cognitive screening, 198, 202–203, 209
Mini-Mental State Examination (MMSE), cognitive screening, 198, 203, 209
Missing data, 19
Montgomery–Asberg Depression Rating Scale (MADRS), 286, 288, 289
Montreal Cognitive Assessment (MOCA), cognitive screening, 198, 204–205, 209
Motor fluctuations, 99–100
Assessment of Parkinson's Disease Scale (APDS), 101–103
CAPSIT—PD diary, 110–111
Future perspectives, 111–112
Hauser Parkinson's Disease Diary, 110–111
Intermediate Scale for Assessment of PD (ISAPD), 103
MDS–UPDRS, 105–106
Methodology, 101
Questionnaires for, detection, 107–109
SCOPA—Motor Scale (S–MS), 104–105
Self evaluation diaries, 109–111
Treatment Response Scale (TRS), 106–107
UPDRS, 103–104
Wearing-Off Questionnaire (WOQ), 108–109
Movement Disorders, 60, 146, 260
Movement Disorder Society (MDS)
Anxiety scales, 187–188
dyskinesia scales, 84, 96
Future developments, 56
Health-related quality of life, 124
Methodology for rating scale review, 59–60
Outcome of rating scales review, 60–61
Task Force for Parkinson's Disease Rating Scales, 14
Movement Disorder Society Unified Parkinson's Disease Scale (MDS–UPDRS), 11, 13, 14, 60
Clinimetric issues, 76–79
Conceptual mapping of items and scores, 72–75
Covered items, 71
Dysautonomia, 218, 223–224, 228
Dyskinesia, 84, 86, 88–89, 96
Evaluation issues, 76–79
Final assessment, 79
Future, 79–80
Handling comorbidities, 76
MCRD and MCRID, 78–79
Motor fluctuations, 101, 102, 105–106
Ratings, 70
Reliability, 77
Responsiveness, 78
Scale description, 70–72, 76
Strengths and weaknesses, 79
Structure, 70–72
Use by multiple authors, 76
Use in PD and across disease spectrum, 76
Validity, 77–78
M-Plus, 14
Multidimensional Fatigue Inventory (MFI), 235, 236, 244–245
Multiple cause structural equation models (MIMIC), 14
National Institute of Neurological Disorders and Stroke (NINDS), 61
Neuropsychiatric disturbances, fatigue and, 237–238
Neuropsychiatric Inventory (NPI), 174
Item 7 (apathy), 175, 176, 179–180
Psychosis, 263, 264, 268–269
Neuropsychiatric Inventory—Anxiety Subscale (NPI–A), 188, 191, 192
New York University Rating Scale (NYURS), 52
Nocturnal sleep scales, 314, 315
Parkinson's Disease Sleep Scale (PDSS and PDSS–2), 308–310
Pittsburgh Sleep Quality Index (PSQI), 310–312
SCOPA–SLEEP, 312–313
Non-Motor Symptoms Questionnaire for Parkinson's Disease (NMS Quest), Dysautonomia, 218, 220–221, 229
Non-Motor Symptoms Scale (NMSS), Dysautonomia, 218, 221–223, 228
Northwestern University Disability Scale (NUDS), 52, 100
Nottingham Health Profile (NHP), 26, 125, 126, 135
Nurses’ Observation Scale for Inpatient Evaluation (NOSIE–30), Psychosis, 263, 264, 274–275
Obeso Dyskinesia Rating Scale (CAPIT), Dyskinesia, 84, 86, 89–90, 96
OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials), 56
Orthostatic Grading Scale (OGS), Dysautonomia, 218, 225–226, 228
Orthostatic hypotension. See also dysautonomia rating scales
Definition and assessment, 216
Prevalence, 215–216
Scales and questionnaires, 216–217, 218
Parkinson, James, 55
Parkinson Disease Dyskinesia Scale (PDYS–26), 26, 84, 86, 93–94, 96
Parkinson Fatigue Scale (PFS), 235, 236, 245–247
Parkinson Neuropsychometric Dementia Assessment (PANDA), Cognitive screening, 198, 206–207, 209
Parkinson Psychosis Questionnaire (PPQ), 263, 264, 265
Parkinson Psychosis Rating Scale (PPRS), 262–265
Parkinson's disease (PD), 5
Anxiety disorders, 186–187
cost-of-illness assessment, 146–149
developments in clinical view, 55–56
Drug-induced dyskinesia, 84–85
History of rating scales, 59–60
Motor fluctuations, 101, 102, 105–106
Ratings, 70
Reliability, 77
Responsiveness, 78
Scale description, 70–72, 76
Strengths and weaknesses, 79
Structure, 70–72
Use by multiple authors, 76
Use in PD and across disease spectrum, 76
Validity, 77–78
M-Plus, 14
Multidimensional Fatigue Inventory (MFI), 235, 236, 244–245
Multiple cause structural equation models (MIMIC), 14
National Institute of Neurological Disorders and Stroke (NINDS), 61
Neuropsychiatric disturbances, fatigue and, 237–238
Neuropsychiatric Inventory (NPI), 174
Item 7 (apathy), 175, 176, 179–180
Psychosis, 263, 264, 268–269
Neuropsychiatric Inventory—Anxiety Subscale (NPI–A), 188, 191, 192
New York University Rating Scale (NYURS), 52
Nocturnal sleep scales, 314, 315
Parkinson’s Disease Sleep Scale (PDSS and PDSS–2), 308–310
Pittsburgh Sleep Quality Index (PSQI), 310–312
SCOPA–SLEEP, 312–313
Non-Motor Symptoms Questionnaire for Parkinson’s Disease (NMS Quest), Dysautonomia, 218, 220–221, 229
Non-Motor Symptoms Scale (NMSS), Dysautonomia, 218, 221–223, 228
Northwestern University Disability Scale (NUDS), 52, 100
Nottingham Health Profile (NHP), 26, 125, 126, 135
Nurses’ Observation Scale for Inpatient Evaluation (NOSIE–30), Psychosis, 263, 264, 274–275
Obeso Dyskinesia Rating Scale (CAPIT), Dyskinesia, 84, 86, 89–90, 96
OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials), 56
Orthostatic Grading Scale (OGS), Dysautonomia, 218, 225–226, 228
Orthostatic hypotension. See also dysautonomia rating scales
Definition and assessment, 216
Prevalence, 215–216
Scales and questionnaires, 216–217, 218
Parkinson, James, 55
Parkinson Disease Dyskinesia Scale (PDYS–26), 26, 84, 86, 93–94, 96
Parkinson Fatigue Scale (PFS), 235, 236, 245–247
Parkinson Neuropsychometric Dementia Assessment (PANDA), Cognitive screening, 198, 206–207, 209
Parkinson Psychosis Questionnaire (PPQ), 263, 264, 265
Parkinson Psychosis Rating Scale (PPRS), 262–265
Parkinson's disease (PD), 5
Anxiety disorders, 186–187
cost-of-illness assessment, 146–149
developments in clinical view, 55–56
drug-induced dyskinesia, 84–85
History of rating scales, 51–52
Term, 125
Unified Parkinson's Disease Rating Scale (UPDRS), 63–70
Parkinson's Disease Cognitive Rating Scale (PD–CRS), 198, 205–206, 209
Parkinson's Disease Dementia–Short Screen (PDDS–SS), Cognitive screening, 198, 206, 209
Parkinson's Disease Impairment Scale, 100
Parkinson's Disease Quality of Life Questionnaire (PDQL), 125, 132, 135
Parkinson's Disease Quality of Life Scale (PDQUALIF), 125, 132–133, 135
Parkinson's Disease Questionnaire (PDQ–39), Quality of life, 125, 130–131, 135
Parkinson's Disease Questionnaire Short Form (PDQ–8), Quality of life, 125, 131, 135
Parkinson's Disease Sleep Scale (PDSS and PDSS–2), 308–310, 314, 315
Parkinson's Impact Scale (PIMS), Quality of life, 125, 131–132, 135
Parkinson's Problem Schedule (PPS), 125, 133–134, 135
Pearson’s coefficients, 11
person-item distribution graph, 33, 34
Person Separation Index (PSI), 29
Phi coefficients, 11
physical fatigue, 237
Pittsburgh Sleep Quality Index (PSQI), 310–312, 314, 315
Positive and Negative Syndrome Scale (PANSS), psychosis, 263, 264, 271–273
precision, 22
principal component analysis, Rasch, 31, 32
Profile of Moods States Questionnaire (POMS), 174
psychometric attributes
Fatigue Impact Scale for Daily Use (D–FIS), 248–249
scale, 18, 24
psychometry, 54
psychosis rating scales
Baylor Hallucinations Questionnaire, 266–267
Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE–AD), 269–270
Brief Psychiatric Rating Scale (BPRS), 270–271
Clinical Global Impression Scale (CGIS), 275–276
dementia, 268–270
Neuropsychiatric Inventory (NPI), 268–269
Nurses’ Observation Scale for Inpatient Evaluation (NOSIE–30), 274–275
occurrence in Parkinson’s disease (PD), 260–262
Parkinson’s disease, 262–268, 275–277
Positive and Negative Syndrome Scale (PANSS), 271–273
proposed diagnostic criteria, 261
recommendations, 277–278
Rush Hallucination Inventory, 265–266
Schedule for Assessment of Positive Symptoms (SAPS), 273–274
schizophrenia, 270–275
University of Miami Parkinson’s Disease Hallucinations Questionnaire (UM–PDHQ), 267–268
UPDRS, 276–277
quality-adjusted life-years (QALYs), 152
Quality of Life Questionnaire 15D (15D)
cost utility, 157, 158, 160, 163
health-related quality of life, 125, 128–129, 135
patients with PD, 153
quality of life scale. See health-related quality of life (HRQL) scales
Quality of Well-Being Scale (QWB)
cost utility, 158, 160, 163
patients with PD, 153
questionnaires. See also health-related quality of life (HRQL) scales; Wearing–Off Questionnaire (WOQ)
Questions on Life Satisfaction–Movement Disorders (QLO–MD) Module, 125, 129–130, 135
Rasch analysis, 18
assessment, 26–34
checklist, 36
choosing version of, 27
differential item functioning (DIF), 31
fit to Rasch model, 27
local independence, 30–31
raw sumscores to linear measure, 33–34, 35
reliability, 28–29
sample size, 28, 29
scale targeting, 31, 33
threshold ordering, 29–30
unidimensionality, 31, 32
Rasch Unidimensional Measurement Models, 27
rating scales
classification, 60
error, 4–5
history in Parkinson’s disease, 51–52
process of developing, 4, 5–9
purpose, 3–4
reliability, 10, 54
classical test theory (CTT), 19–20
Hoehn and Yahr (HY) scale, 119
MDS–UPDRS, 77
Rasch analysis, 28–29
scale development, 11–12
UPDRS, 65–66
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), cognitive screening, 198, 207–208, 209
reproducibility, scale attribute, 24
Resource Utilization Instrument for Dementia (RUD), 164, 165
respondent burden, 25–26
responsiveness, 54
classical test theory (CTT), 22–23, 24
Hoehn and Yahr (HY) scale, 119
MDS–UPDRS, 78
UPDRS, 66
Ribot, Théodule, 174
Root-mean-square error (RMSE), 13
Rösser disability/distress scale
cost utility, 158, 160, 162
patients with PD, 154
Rush Dyskinesia Rating Scale, dyskinesia, 84, 86, 90–91, 96
Rush Hallucination Inventory, 263, 264, 265–266
scale targeting, 31, 33
scatter plot, 21
Schedule for Assessment of Positive Symptoms (SAPS), 273–274
psychosis
Schizophrenia, psychosis scales, 270–275
Schwab and England scale, 52, 67
SCOPA–AUT (Autonomic Scale for Outcomes in Parkinson’s disease), 26
dysautonomia, 217, 218, 219, 228
SCOPA–COG (Scales for Outcomes in Parkinson’s Disease–Cognition), 26, 27
cognitive screening, 198, 208, 209, 210
SCOPA–Motor Scale (S–MS), motor fluctuations, 101, 102, 104–105
SCOPA–PS (Scales for Outcomes in Parkinson’s Disease–Psychosocial), 27
category probability curve, 30
differential item functioning (DIF), 33
global fit to Rasch model, 28
individual item fit, 29
person–item residual correlation, 31
principal component analysis, 32
quality of life, 125, 134, 135
Rasch analysis, 28–35
raw sumscores to linear measure, 35
reliability, 29
sample size and descriptives, 29
threshold ordering, 28
t-test values, 32
SCOPA–sleep scale, 19, 312–313, 314, 315
self-evaluation diaries, motor fluctuations, 99, 101, 109–111
Self-Rating Anxiety Scale (SAS), 188, 189–190, 192
Self-Rating Depression Scale (SDS), 286, 288, 292
Senard et al. 1997, dysautonomia, 218, 226, 229
sensitivity-based approach, minimal clinically relevant change (MCRC), 44
severity, domain and scaling, 7
SF–36. See Medical Outcomes Study 36-Item Short Form Health Survey (SF–36)
Short Parkinson’s Evaluation Scale (SPES), 104
Sickness Impact Profile (SIP), health-related quality of life, 125–126, 135
sleep disturbances. See also nocturnal sleep scales
Parkinson’s disease, 307–308
sleep scale, 10
Snith-Hamilton Pleasure Scale (SHAPS), 175, 176, 181
social comparison approach, MCRC, 44
sociometry, 54
Spearman’s coefficients, 11
specificity-based approach, minimal clinically relevant change (MCRC), 44
Stacy questionnaire, WOQ–32, 100, 101, 107–109
standard deviation, 45
standard error of measurement (SEM), 22, 45
standard error variance (SEM), 22
standard gamble (SG), cost utility (CU), 152
State Trait Anxiety Inventory (STAI), 188, 190, 192
statistics
cognitive pretesting, 11
content evidence, 11
differential item functioning (DIF), 14
factor analysis, 12–13
future, 14
internal consistency, 12
measuring change over time, 13–14
reliability, 11–12
subgroup differentiation, 13–14
summary indexes, 21
tariffs, 161
test–retest reliability, 11
Tests in Print, 5
time trade-off (TTO), cost utility, 156
Treatment Response Scale (TRS), motor fluctuations, 101, 102, 106–107
t–tests, 23, 32
Unified Dyskinesia Rating Scale (UDysRS), dyskinesia, 84, 86, 94–95, 96
Unified Parkinson’s Disease Rating Scale (UPDRS), 13, 52, 53, 59
clinimetric issues, 65–69
conceptual mapping of items and scores, 72–75
depression, 286, 288, 295
dysautonomia, 218, 223–224, 229
dyskinesia, 84, 86, 87–88, 96
evaluation issues, 64–69
final assessment, 69–70
handling comorbidities, 63–64
internal validity, 23
item 4 (motivation/initiative), 174, 175, 176, 179
MCRD, MCIC and MCRID, 66–68
motor fluctuations, 101, 103–104
Movement Disorder Society (MDS) revision, 14, 60
psychosis, 263, 264, 276–277
ratings, 70
reliability, 65–66
responsiveness, 66
scale description, 63–64
strengths and weaknesses, 68–69
structure, 63
use by multiple authors, 65
use in PD and across disease spectrum, 64–65
validity, 66
University of Miami Parkinson’s Disease Hallucinations Questionnaire (UM–PDHQ), 263, 264, 267–268
validation, scale, 17–18
validity, 10, 54
classical test theory (CTT), 20–22
Hoehn and Yahr (HY) scale, 118–119
MDS–UPDRS, 77–78
UPDRS, 66
Visual Analogue Scale (VAS)
cost utility, 156
fatigue, 235, 236, 250–251
patients with PD, 153
Wearing-Off Questionnaire (WOQ)
QQ–WOQ, 101, 107, 109
WOQ–19, 100, 101, 108–109
WOQ–32, 100, 101, 107, 108–109
WOQ–9, 100, 101, 107, 108–109
Webster scale, 52
WHO Quality of Life Assessment Short Version (WHOQOL–BREF), health-related quality of life, 125, 129, 135
“within-patients” score change, minimal clinically relevant change (MCRC), 44
World Health Organization (WHO), 124
Zung Self-Rating Anxiety Scale (SAS), 188, 189–190, 192
Zung Self-Rating Depression Scale (SDS), 286, 288, 292
z-values, 23